Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Hamm C) "

Sökning: WFRF:(Hamm C)

  • Resultat 1-10 av 37
  • [1]234Nästa
Sortera/gruppera träfflistan
  • Forstner, A. J., et al. (författare)
  • Genome-wide association study of panic disorder reveals genetic overlap with neuroticism and depression
  • 2019
  • Ingår i: Molecular Psychiatry. - 1359-4184 .- 1476-5578.
  • Tidskriftsartikel (refereegranskat)abstract
    • Panic disorder (PD) has a lifetime prevalence of 2–4% and heritability estimates of 40%. The contributory genetic variants remain largely unknown, with few and inconsistent loci having been reported. The present report describes the largest genome-wide association study (GWAS) of PD to date comprising genome-wide genotype data of 2248 clinically well-characterized PD patients and 7992 ethnically matched controls. The samples originated from four European countries (Denmark, Estonia, Germany, and Sweden). Standard GWAS quality control procedures were conducted on each individual dataset, and imputation was performed using the 1000 Genomes Project reference panel. A meta-analysis was then performed using the Ricopili pipeline. No genome-wide significant locus was identified. Leave-one-out analyses generated highly significant polygenic risk scores (PRS) (explained variance of up to 2.6%). Linkage disequilibrium (LD) score regression analysis of the GWAS data showed that the estimated heritability for PD was 28.0–34.2%. After correction for multiple testing, a significant genetic correlation was found between PD and major depressive disorder, depressive symptoms, and neuroticism. A total of 255 single-nucleotide polymorphisms (SNPs) with p < 1 × 10−4 were followed up in an independent sample of 2408 PD patients and 228,470 controls from Denmark, Iceland and the Netherlands. In the combined analysis, SNP rs144783209 showed the strongest association with PD (pcomb = 3.10 × 10−7). Sign tests revealed a significant enrichment of SNPs with a discovery p-value of <0.0001 in the combined follow up cohort (p = 0.048). The present integrative analysis represents a major step towards the elucidation of the genetic susceptibility to PD. © 2019, The Author(s), under exclusive licence to Springer Nature Limited.
  • Neumann, J. T., et al. (författare)
  • Application of High-Sensitivity Troponin in Suspected Myocardial Infarction
  • 2019
  • Ingår i: New England Journal of Medicine. - : MASSACHUSETTS MEDICAL SOC. - 0028-4793 .- 1533-4406. ; 380:26, s. 2529-2540
  • Tidskriftsartikel (refereegranskat)abstract
    • BackgroundData regarding high-sensitivity troponin concentrations in patients presenting to the emergency department with symptoms suggestive of myocardial infarction may be useful in determining the probability of myocardial infarction and subsequent 30-day outcomes. MethodsIn 15 international cohorts of patients presenting to the emergency department with symptoms suggestive of myocardial infarction, we determined the concentrations of high-sensitivity troponin I or high-sensitivity troponin T at presentation and after early or late serial sampling. The diagnostic and prognostic performance of multiple high-sensitivity troponin cutoff combinations was assessed with the use of a derivation-validation design. A risk-assessment tool that was based on these data was developed to estimate the risk of index myocardial infarction and of subsequent myocardial infarction or death at 30 days. ResultsAmong 22,651 patients (9604 in the derivation data set and 13,047 in the validation data set), the prevalence of myocardial infarction was 15.3%. Lower high-sensitivity troponin concentrations at presentation and smaller absolute changes during serial sampling were associated with a lower likelihood of myocardial infarction and a lower short-term risk of cardiovascular events. For example, high-sensitivity troponin I concentrations of less than 6 ng per liter and an absolute change of less than 4 ng per liter after 45 to 120 minutes (early serial sampling) resulted in a negative predictive value of 99.5% for myocardial infarction, with an associated 30-day risk of subsequent myocardial infarction or death of 0.2%; a total of 56.5% of the patients would be classified as being at low risk. These findings were confirmed in an external validation data set. ConclusionsA risk-assessment tool, which we developed to integrate the high-sensitivity troponin I or troponin T concentration at emergency department presentation, its dynamic change during serial sampling, and the time between the obtaining of samples, was used to estimate the probability of myocardial infarction on emergency department presentation and 30-day outcomes.
  • Schiele, Miriam A., et al. (författare)
  • Therapygenetic effects of 5-HTTLPR on cognitive-behavioral therapy in anxiety disorders : A meta-analysis
  • 2021
  • Ingår i: European Neuropsychopharmacology. - : Elsevier. - 0924-977X .- 1873-7862. ; 44, s. 105-120
  • Tidskriftsartikel (refereegranskat)abstract
    • There is a recurring debate on the role of the serotonin transporter gene linked polymorphic region (5-HTTLPR) in the moderation of response to cognitive behavioral therapy (CBT) in anxiety disorders. Results, however, are still inconclusive. We here aim to perform a meta-analysis on the role of 5-HTTLPR in the moderation of CBT outcome in anxiety disorders. We investigated both categorical (symptom reduction of at least 50%) and dimensional outcomes from baseline to post-treatment and follow-up. Original data were obtained from ten independent samples (including three unpublished samples) with a total of 2,195 patients with primary anxiety disorder. No significant effects of 5-HTTLPR genotype on categorical or dimensional outcomes at post and follow-up were detected. We conclude that current evidence does not support the hypothesis of 5-HTTLPR as a moderator of treatment outcome for CBT in anxiety disorders. Future research should address whether other factors such as long-term changes or epigenetic processes may explain further variance in these complex gene-environment interactions and molecular-genetic pathways that may confer behavioral change following psychotherapy.
  • Pajola, M., et al. (författare)
  • The Agilkia boulders/pebbles size-frequency distributions : OSIRIS and ROLIS joint observations of 67P surface
  • 2016
  • Ingår i: Monthly notices of the Royal Astronomical Society. - 0035-8711 .- 1365-2966. ; 462, s. S242-S252
  • Tidskriftsartikel (refereegranskat)abstract
    • By using the images acquired by the OSIRIS (Optical, Spectroscopic and Infrared Remote Imaging System) and ROLIS (ROsetta Lander Imaging System) cameras, we derive the size-frequency distribution (SFD) of cometary pebbles and boulders covering the size range 0.05-30.0 m on the Agilkia landing site. The global SFD measured on OSIRIS images, reflects the different properties of the multiple morphological units present on Agilkia, combined with selection effects related to lifting, transport and redeposition. Contrarily, the different ROLIS SFD derived on the smooth and rough units may be related to their different regolith thickness present on Agilkia. In the thicker, smoother layer, ROLIS mainly measures the SFD of the airfall population which almost completely obliterates the signature of underlying boulders up to a size of the order of 1 m. This is well matched by the power-law index derived analysing coma particles identified by the grain analyser Grain Impact Analyser and Dust Accumulator. This result confirms the important blanketing dynamism of Agilkia. The steeper SFD observed in rough terrains from 0.4 to 2 m could point out intrinsic differences between northern and southern dust size distributions, or it may suggest that the underlying boulders 'peek through' the thinner airfall layer in the rough terrain, thereby producing the observed excess in the decimetre size range. Eventually, the OSIRIS SFD performed on the Philae landing unit may be due to water sublimation from a static population of boulders, affecting smaller boulders before the bigger ones, thus shallowing the original SFD.
  • Bonaca, M. P., et al. (författare)
  • Reduction in subtypes and sizes of myocardial infarction with ticagrelor in PEGASUS-TIMI 54
  • 2018
  • Ingår i: Journal of the American Heart Association. - 2047-9980. ; 7:22
  • Tidskriftsartikel (refereegranskat)abstract
    • Background-—Ticagrelor reduced cardiovascular death, myocardial infarction (MI), or stroke in patients with prior MI in PEGASUSTIMI 54 (Prevention of Cardiovascular Events [eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke] in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin). MI can occur in diverse settings and with varying severity; therefore, understanding the types and sizes of MI events prevented is of clinical importance. Methods and Results-—MIs were adjudicated by a blinded clinical events committee and categorized by subtype and fold elevation of peak cardiac troponin over the upper limit of normal. A total of 1042 MIs occurred in 898 of the 21 162 randomized patients over a median follow-up of 33 months. The majority of the MIs (76%) were spontaneous (Type 1), with demand MI (Type 2) and stent thrombosis (Type 4b) accounting for 13% and 9%, respectively; sudden death (Type 3), percutaneous coronary intervention–related (Type 4a) and coronary artery bypass graft–related (Type 5) each accounted for <1%. Half of MIs (520, 50%) had a peak troponin ≥10x upper limit of normal and 21% of MIs (220) had a peak troponin ≥1009 upper limit of normal. A total of 21% (224) were ST-segment–elevation MI STEMI. Overall ticagrelor reduced MI (4.47% versus 5.25%, hazard ratio 0.83, 95% confidence interval 0.72–0.95, P=0.0055). The benefit was consistent among the subtypes, including a 31% reduction in MIs with a peak troponin ≥1009 upper limit of normal (hazard ratio 0.69, 95% confidence interval 0.53–0.92, P=0.0096) and a 40% reduction in ST-segment elevation MI (hazard ratio 0.60, 95% confidence interval 0.46–0.78, P=0.0002). Conclusions-—In stable outpatients with prior MI, the majority of recurrent MIs are spontaneous and associated with a high biomarker elevation. Ticagrelor reduces the MI consistently among subtypes and sizes including large MIs and ST-segment elevation MI. Clinical Trial Registration-URL: https://www.clinicaltrials.gov. Unique identifier: NCT01225562. © 2018 The Authors.
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 37
  • [1]234Nästa
Typ av publikation
tidskriftsartikel (34)
forskningsöversikt (2)
annan publikation (1)
Typ av innehåll
refereegranskat (35)
övrigt vetenskapligt (2)
Hamm, C (14)
Bax, Jeroen J (6)
Katus, Hugo A (5)
Ruck, C (5)
Hamm, Christian W. (5)
Andersson, E (4)
visa fler...
Mueller, C. (4)
Giannitsis, E (4)
Armstrong, Paul W. (4)
White, Harvey D. (4)
Reif, A. (4)
Lindefors, N (4)
Jaffe, Allan S. (4)
Arolt, V (4)
Domschke, K (4)
Mottola, S. (4)
Newby, L Kristin (4)
Simoons, Maarten L (4)
Bassand, Jean-Pierre (4)
Wijns, William (4)
Bueno, H (4)
Fox, Keith A (4)
Clemmensen, Peter M. (4)
Parkhomenko, Alexand ... (4)
Alpert, Joseph S (4)
Antman, Elliott M (4)
Pauli, P (4)
Dellborg, Mikael, 19 ... (3)
Aboyans, V (3)
Lavebratt, C (3)
Tendera, Michal (3)
Filippatos, Gerasimo ... (3)
Ponikowski, P (3)
Walther, T. (3)
Wolf, C (3)
Vincent, J. -B (3)
Knollenberg, J. (3)
Lindahl, Bertil (3)
Schalling, M (3)
Ohman, E. Magnus (3)
Wittchen, HU (3)
Merkely, B (3)
Thygesen, Kristian (3)
Hagermann, Axel (3)
Grott, M. (3)
Katus, HA (3)
Lubinski, A (3)
Vahanian, Alec (3)
Wallentin, Lars C. (3)
Tubaro, M (3)
visa färre...
Karolinska Institutet (14)
Uppsala universitet (12)
Göteborgs universitet (6)
Luleå tekniska universitet (3)
Linnéuniversitetet (3)
Umeå universitet (1)
visa fler...
Kungliga Tekniska Högskolan (1)
Stockholms universitet (1)
Linköpings universitet (1)
Lunds universitet (1)
visa färre...
Engelska (37)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (12)
Naturvetenskap (6)
Teknik (1)
Samhällsvetenskap (1)


pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy